Semax

Background

Semax was developed in the early 1980s at Moscow State University by Ivan Ashmarin's group. The design rationale was to take the behaviorally active fragment of ACTH — the 4-10 sequence — and stabilize it against rapid enzymatic degradation by appending a Pro-Gly-Pro tail. The result is a heptapeptide with no corticotropic (steroid-stimulating) activity but retained neurotropic effects.

It has been used clinically in Russia for decades for ischemic stroke, transient ischemic attack, and cognitive impairment. Outside Russia it occupies a gray zone: clearly active, but with regulatory and clinical-trial documentation that does not meet Western standards.

Mechanism in depth

Semax is an ACTH(4-10) analog but does not bind the corticotropic melanocortin receptors. Its known actions include:

1. BDNF and NGF expression. Acute dosing raises hippocampal and cortical BDNF mRNA within 30–60 minutes. This is reproducible across multiple Russian labs and at least one Western replication.
2. Modulation of monoamine systems. Increases extracellular dopamine in striatum and serotonin turnover in cortex, measured by microdialysis in rats.
3. Anti-inflammatory effects in ischemic tissue. Reduced microglial activation and pro-inflammatory cytokines in stroke models.
4. Endogenous opioid potentiation. Semax appears to potentiate enkephalin signaling, which may contribute to its mood and anxiolytic effects.

Human evidence

The clinical use case in Russia is well established but the trial methodology is uneven:

• Stroke trials. Multiple Russian RCTs report improved NIHSS scores and reduced edema. Sample sizes are modest (n=50–200) and blinding details are sometimes unclear.
• Cognitive impairment. Open-label and quasi-controlled studies in vascular cognitive impairment, mild ADHD, and post-concussive syndrome generally show modest improvement.
• Healthy nootropic use. Essentially no formal data. All claims rest on extrapolation.

Animal evidence

Robust:

• Reduced infarct volume in MCAO stroke models.
• Improved learning in passive avoidance and water maze in aged rats.
• Anxiolytic-like behavior in elevated plus maze without sedation.
• Neuroprotection against amyloid-beta toxicity in cultured neurons.

Stack synergy

Commonly paired with:

• Selank — another Russian heptapeptide (Tuftsin analog) with anxiolytic action. The Semax + Selank combination is the canonical Russian nootropic stack.
• Cerebrolysin — overlapping neurotrophic rationale.
• Caffeine — mild additive stimulation; not pharmacologically remarkable.

Avoid stacking with strong dopaminergic agents (high-dose modafinil, amphetamines) without dose attention — Semax's dopaminergic component can be additive.

Open questions

• Does chronic Semax produce sustained BDNF elevation or does the system downregulate?
• What is the optimal dosing interval — twice daily, once daily, or pulsed?
• Are the stroke benefits real at the magnitude reported, and would they replicate under Western trial standards?
• Is there a healthy-user benefit at all, or is the effect specific to deficit states (post-stroke, MCI, chronic stress)?